BioSpace News Archive

- Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314

The generous donation will support burn survivor healing through major initiatives surrounding patient and family care, virtual programming and peer support

Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a single healthcare-dedicated institutional investor for the purchase and sale of 3,116,884 shares of its common stock at a purchase price of $3.85 per share in a register

Today, the U.S. Food and Drug Administration issued five warning letters to companies for selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). All five warning letters address the illegal marketing of unapproved CBD products claiming to treat medical condit

Fuse Medical, Inc. (OTCPINK: FZMD) (“Fuse” or the “Company”), an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced the initial launch of FuseChoice TM and FuseChoice TM Plus Amniotic & Umbilical Membranes, and FuseChoice TM Plus Amniotic Joint Cushioning Fluid, the latest

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company’s board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and

Guidelines provide recommendations on the diagnosis and management of glaucoma within the EU Nine MicroPulse TLT studies presented at the annual EGS meeting supporting its safety, effectiveness, and versatility in the treatment of glaucoma

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it will host and webcast a virtual investor briefing at the 2

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schroer, the Company’s Chief Financial Officer (CFO), is departing the Company for personal reasons. Mr. Schroer’s departure will be effective by year-end 2020. Robert Prentiss, Translate Bio’s Vice Presid

Healthcare Services Acquisition Corporation (the “Company”) today announced the pricing of its upsized initial public offering of 28,800,000 units at a price of $10.00 per unit.